{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T11:59:30Z","timestamp":1774958370604,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Endocrine Society of India","award":["RG1"],"award-info":[{"award-number":["RG1"]}]},{"name":"Indian Society for Bone and Mineral Research","award":["2022"],"award-info":[{"award-number":["2022"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00198-025-07599-7","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T16:21:57Z","timestamp":1751300517000},"page":"1633-1639","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Anti-resorptive and anabolic therapies improve Falls Risk Assessment Score (FRAS) in postmenopausal women with type 2 diabetes mellitus"],"prefix":"10.1007","volume":"36","author":[{"given":"Trupti N.","family":"Prasad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep Singh","family":"Flora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay K.","family":"Bhadada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urmila","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rimesh","family":"Pal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"7599_CR1","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1056\/NEJMcp1903252","volume":"382","author":"DA Ganz","year":"2020","unstructured":"Ganz DA, Latham NK (2020) Prevention of falls in community-dwelling older adults. N Engl J Med 382:734\u2013743. https:\/\/doi.org\/10.1056\/NEJMcp1903252","journal-title":"N Engl J Med"},{"key":"7599_CR2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.cger.2014.09.002","volume":"31","author":"AI Vinik","year":"2015","unstructured":"Vinik AI, Vinik EJ, Colberg SR, Morrison S (2015) Falls risk in older adults with type 2 diabetes. Clin Geriatr Med 31:89\u201399. https:\/\/doi.org\/10.1016\/j.cger.2014.09.002","journal-title":"Clin Geriatr Med"},{"key":"7599_CR3","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1080\/09638288.2016.1199741","volume":"39","author":"J Gravesande","year":"2017","unstructured":"Gravesande J, Richardson J (2017) Identifying non-pharmacological risk factors for falling in older adults with type 2 diabetes mellitus: a systematic review. Disabil Rehabil 39:1459\u20131465. https:\/\/doi.org\/10.1080\/09638288.2016.1199741","journal-title":"Disabil Rehabil"},{"key":"7599_CR4","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.4158\/EP171794.RA","volume":"23","author":"AI Vinik","year":"2017","unstructured":"Vinik AI, Camacho P, Reddy S et al (2017) Aging, diabetes, and falls. Endocr Pract 23:1120\u20131142. https:\/\/doi.org\/10.4158\/EP171794.RA","journal-title":"Endocr Pract"},{"key":"7599_CR5","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41574-022-00707-1","volume":"18","author":"R Pal","year":"2022","unstructured":"Pal R, Prasad TN, Bhadada SK (2022) Bone fragility in type 2 diabetes mellitus: a lot left to explore. Nat Rev Endocrinol 18:651\u2013651. https:\/\/doi.org\/10.1038\/s41574-022-00707-1","journal-title":"Nat Rev Endocrinol"},{"key":"7599_CR6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/MED.0000000000000640","volume":"28","author":"R Pal","year":"2021","unstructured":"Pal R, Bhadada SK (2021) Bone health in diabetes: Indian perspective. Curr Opin Endocrinol Diabetes Obes 28:383\u2013389. https:\/\/doi.org\/10.1097\/MED.0000000000000640","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"7599_CR7","doi-asserted-by":"publisher","first-page":"R55","DOI":"10.1530\/EC-18-0456","volume":"8","author":"A-K Picke","year":"2019","unstructured":"Picke A-K, Campbell G, Napoli N et al (2019) Update on the impact of type 2 diabetes mellitus on bone metabolism and material properties. Endocr Connect 8:R55\u2013R70. https:\/\/doi.org\/10.1530\/EC-18-0456","journal-title":"Endocr Connect"},{"key":"7599_CR8","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, Martin JS, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765. https:\/\/doi.org\/10.1056\/NEJMoa0809493","journal-title":"N Engl J Med"},{"key":"7599_CR9","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1007\/s10067-021-05757-w","volume":"40","author":"YE Miedany","year":"2021","unstructured":"Miedany YE, Gaafary ME, Toth M et al (2021) Is there a potential dual effect of denosumab for treatment of osteoporosis and sarcopenia? Clin Rheumatol 40:4225\u20134232. https:\/\/doi.org\/10.1007\/s10067-021-05757-w","journal-title":"Clin Rheumatol"},{"key":"7599_CR10","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/jbmr.3972","volume":"35","author":"P Chotiyarnwong","year":"2020","unstructured":"Chotiyarnwong P, McCloskey E, Eastell R et al (2020) A pooled analysis of fall incidence from placebo-controlled trials of denosumab. J Bone Miner Res 35:1014\u20131021. https:\/\/doi.org\/10.1002\/jbmr.3972","journal-title":"J Bone Miner Res"},{"key":"7599_CR11","doi-asserted-by":"publisher","first-page":"204201882312075","DOI":"10.1177\/20420188231207516","volume":"14","author":"TN Prasad","year":"2023","unstructured":"Prasad TN, Bhadada SK, Singla V et al (2023) Efficacy of zoledronate, denosumab or teriparatide in postmenopausal women with type 2 diabetes mellitus at high risk of fragility fractures: protocol of an open, blinded endpoint randomized controlled pilot trial. Ther Adv Endocrinol Metab 14:20420188231207516. https:\/\/doi.org\/10.1177\/20420188231207516","journal-title":"Ther Adv Endocrinol Metab"},{"key":"7599_CR12","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11657-024-01450-y","volume":"19","author":"R Pal","year":"2024","unstructured":"Pal R, Prasad TN, Bhadada SK et al (2024) Association between bone microarchitecture and sarcopenia in postmenopausal women with type 2 diabetes. Arch Osteoporos 19:94. https:\/\/doi.org\/10.1007\/s11657-024-01450-y","journal-title":"Arch Osteoporos"},{"key":"7599_CR13","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11657-020-00756-x","volume":"15","author":"R Rajan","year":"2020","unstructured":"Rajan R, Paul J, Cherian KE et al (2020) FRAX\u00ae with or without BMD and TBS predicts fragility fractures in community-dwelling rural southern Indian postmenopausal women. Arch Osteoporos 15:82. https:\/\/doi.org\/10.1007\/s11657-020-00756-x","journal-title":"Arch Osteoporos"},{"key":"7599_CR14","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s41999-020-00332-z","volume":"11","author":"R Pal","year":"2020","unstructured":"Pal R, Aggarwal A, Singh T et al (2020) Diagnostic cut-offs, prevalence, and biochemical predictors of sarcopenia in healthy Indian adults: the sarcopenia-chandigarh urban bone epidemiological study (sarco-cubes). Eur Geriatr Med 11:725\u2013736. https:\/\/doi.org\/10.1007\/s41999-020-00332-z","journal-title":"Eur Geriatr Med"},{"key":"7599_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jcgg.2011.01.002","volume":"2","author":"Y El Miedany","year":"2011","unstructured":"El Miedany Y, El Gaafary M, Toth M et al (2011) Falls risk assessment score (FRAS): time to rethink. J Clin Gerontol Geriatr 2:21\u201326. https:\/\/doi.org\/10.1016\/j.jcgg.2011.01.002","journal-title":"J Clin Gerontol Geriatr"},{"key":"7599_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S1836-9553(13)70160-7","volume":"59","author":"L McPhate","year":"2013","unstructured":"McPhate L, Simek EM, Haines TP (2013) Program-related factors are associated with adherence to group exercise interventions for the prevention of falls: a systematic review. J Physiother 59:81\u201392. https:\/\/doi.org\/10.1016\/S1836-9553(13)70160-7","journal-title":"J Physiother"},{"key":"7599_CR17","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1111\/jgs.16165","volume":"67","author":"S Phu","year":"2019","unstructured":"Phu S, Bani Hassan E, Vogrin S et al (2019) Effect of denosumab on falls, muscle strength, and function in community-dwelling older adults. J Am Geriatr Soc 67:2660\u20132661. https:\/\/doi.org\/10.1111\/jgs.16165","journal-title":"J Am Geriatr Soc"},{"key":"7599_CR18","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1007\/s00198-022-06470-3","volume":"33","author":"T Rupp","year":"2022","unstructured":"Rupp T, Von Vopelius E, Strahl A et al (2022) Beneficial effects of denosumab on muscle performance in patients with low BMD: a retrospective, propensity score-matched study. Osteoporos Int 33:2177\u20132184. https:\/\/doi.org\/10.1007\/s00198-022-06470-3","journal-title":"Osteoporos Int"},{"key":"7599_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.57582\/IJBF.240401.002","volume":"4","author":"G Voltan","year":"2024","unstructured":"Voltan G, Veronese N (2024) The role of anti-osteoporosis drugs in fall risk. Int J Bone Fragility 4:2\u20138. https:\/\/doi.org\/10.57582\/IJBF.240401.002","journal-title":"Int J Bone Fragility"},{"key":"7599_CR20","doi-asserted-by":"publisher","first-page":"C663","DOI":"10.1152\/ajpcell.00285.2015","volume":"310","author":"SS Dufresne","year":"2016","unstructured":"Dufresne SS, Dumont NA, Boulanger-Piette A et al (2016) Muscle RANK is a key regulator of Ca2+ storage, SERCA activity, and function of fast-twitch skeletal muscles. Am J Physiol-Cell Physiol 310:C663\u2013C672. https:\/\/doi.org\/10.1152\/ajpcell.00285.2015","journal-title":"Am J Physiol-Cell Physiol"},{"key":"7599_CR21","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3390\/ph16020162","volume":"16","author":"HN Rubaiy","year":"2023","unstructured":"Rubaiy HN (2023) ORAI calcium channels: regulation, function, pharmacology, and therapeutic targets. Pharmaceuticals 16:162. https:\/\/doi.org\/10.3390\/ph16020162","journal-title":"Pharmaceuticals"},{"key":"7599_CR22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.cophys.2020.06.006","volume":"17","author":"M Sallinger","year":"2020","unstructured":"Sallinger M, Berlansky S, Frischauf I (2020) Orai channels: key players in Ca2+ homeostasis. Curr Opin Physiol 17:42\u201349. https:\/\/doi.org\/10.1016\/j.cophys.2020.06.006","journal-title":"Curr Opin Physiol"},{"key":"7599_CR23","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.cophys.2020.07.006","volume":"17","author":"M Fahrner","year":"2020","unstructured":"Fahrner M, Grabmayr H, Romanin C (2020) Mechanism of STIM activation. Curr Opin Physiol 17:74\u201379. https:\/\/doi.org\/10.1016\/j.cophys.2020.07.006","journal-title":"Curr Opin Physiol"},{"key":"7599_CR24","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1172\/JCI125915","volume":"129","author":"N Bonnet","year":"2019","unstructured":"Bonnet N, Bourgoin L, Biver E et al (2019) RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass. J Clin Invest 129:3214\u20133223. https:\/\/doi.org\/10.1172\/JCI125915","journal-title":"J Clin Invest"},{"key":"7599_CR25","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.2147\/DDDT.S328858","volume":"15","author":"C-F Huang","year":"2021","unstructured":"Huang C-F, Shiao M-S, Mao T-Y (2021) Retrospective study of the effects of zoledronic acid on muscle mass in osteoporosis patients. Drug Des Devel Ther 15:3711\u20133715. https:\/\/doi.org\/10.2147\/DDDT.S328858","journal-title":"Drug Des Devel Ther"},{"key":"7599_CR26","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1097\/GME.0b013e31827cabca","volume":"20","author":"JH Park","year":"2013","unstructured":"Park JH, Park KH, Cho S et al (2013) Concomitant increase in muscle strength and bone mineral density with decreasing IL-6 levels after combination therapy with alendronate and calcitriol in postmenopausal women. Menopause 20:747\u2013753. https:\/\/doi.org\/10.1097\/GME.0b013e31827cabca","journal-title":"Menopause"},{"key":"7599_CR27","doi-asserted-by":"publisher","first-page":"420","DOI":"10.14283\/jfa.2022.54","volume":"11","author":"NS Haeri","year":"2022","unstructured":"Haeri NS, Perera S, Greenspan SL (2022) Does Zoledronic Acid improve appendicular lean mass in older women with osteoporosis? A sub-analysis of a randomized clinical trial. J Frailty Aging 11:420\u2013425. https:\/\/doi.org\/10.14283\/jfa.2022.54","journal-title":"J Frailty Aging"},{"key":"7599_CR28","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/jcsm.12289","volume":"9","author":"H Chiu","year":"2018","unstructured":"Chiu H, Chiu C, Yang R et al (2018) Preventing muscle wasting by osteoporosis drug alendronate in vitro and in myopathy models via sirtuin-3 down-regulation. J Cachexia Sarcopenia Muscle 9:585\u2013602. https:\/\/doi.org\/10.1002\/jcsm.12289","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"7599_CR29","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1186\/s12891-024-08054-0","volume":"25","author":"W Li","year":"2024","unstructured":"Li W, Xu M, Shi X et al (2024) Effect of zoledronic acid on muscle metabolism in mice with osteoporosis combined with sarcopenia. BMC Musculoskelet Disord 25:937. https:\/\/doi.org\/10.1186\/s12891-024-08054-0","journal-title":"BMC Musculoskelet Disord"},{"key":"7599_CR30","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00774-020-01184-0","volume":"39","author":"C Sato","year":"2021","unstructured":"Sato C, Miyakoshi N, Kasukawa Y et al (2021) Teriparatide and exercise improve bone, skeletal muscle, and fat parameters in ovariectomized and tail-suspended rats. J Bone Miner Metab 39:385\u2013395. https:\/\/doi.org\/10.1007\/s00774-020-01184-0","journal-title":"J Bone Miner Metab"},{"key":"7599_CR31","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.bone.2019.01.028","volume":"121","author":"S-H Yoon","year":"2019","unstructured":"Yoon S-H, Grynpas M, Mitchell J (2019) Intermittent PTH treatment improves bone and muscle in glucocorticoid treated Mdx mice: a model of Duchenne Muscular Dystrophy. Bone 121:232\u2013242. https:\/\/doi.org\/10.1016\/j.bone.2019.01.028","journal-title":"Bone"},{"key":"7599_CR32","doi-asserted-by":"publisher","first-page":"116029","DOI":"10.1016\/j.bone.2021.116029","volume":"151","author":"T Fujimaki","year":"2021","unstructured":"Fujimaki T, Ando T, Hata T et al (2021) Exogenous parathyroid hormone attenuates ovariectomy-induced skeletal muscle weakness in vivo. Bone 151:116029. https:\/\/doi.org\/10.1016\/j.bone.2021.116029","journal-title":"Bone"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07599-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-025-07599-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07599-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T21:03:35Z","timestamp":1758747815000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-025-07599-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["7599"],"URL":"https:\/\/doi.org\/10.1007\/s00198-025-07599-7","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"assertion":[{"value":"26 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institute ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed written consent was obtained from all the participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}